3D Cell Culture is gaining momentum in the pharmaceutical industry, with the global 3D Cell Culture market predicted to surpass a value of $3.2 Billion by 2027. Researchers globally are realising the potential of in vitro applications for drug discovery, predictivity and validation, safety, and toxicity.
SMi’s 5th Annual 3D Cell Culture Conference will be covering the application of 3D cell culture to drug development, toxicity testing, and safety assurance. In addition, the conference will look into the newest breakthroughs in Organ Chip technology, 3D Multicellular scaffolding, Microphysiological Systems, and 3D Bioprinting. In recent years technological advances have made these technologies viable and accessible in scientific application.
Event Hashtag: #SMi3DCellCulture
HIGHLIGHTS FOR 2021
WHO SHOULD ATTEND?
Biotech / Pharma Companies - Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor - Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO
Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer
SMi’s 5th Annual 3D Cell Culture Conference will be covering the application of 3D cell culture to drug development, toxicity testing, and safety assurance. In addition, the conference will look into the newest breakthroughs in Organ Chip technology, 3D Multicellular scaffolding, Microphysiological Systems, and 3D Bioprinting. In recent years technological advances have made these technologies viable and accessible in scientific application.
Event Hashtag: #SMi3DCellCulture
HIGHLIGHTS FOR 2021
- Discover the cutting-edge technology that is changing the face of pharmaceutical drug development
- Explore the necessity of utilising 3D models in the cytotoxic testing of biologics over traditional alternatives
- Insight into the capacity for microphysiological systems and organ-on-a-chip technology to mimic cellular microenvironments in vitro
- Discuss current case studies in applied 3D cell models that are changing the future of pharmaceutical drug discovery
- Assess the biophysiological competency of MPS and 3D Bioprinting at the pre-conference workshops
- Suzanne Fitzpatrick, Senior Advisor for Toxicology, US Food and Drug Administration
- Pelin Candarlioglu, Investigator - Bioengineer/Cell Biologist, GSK
- Robert Vries, CEO, Hubrecht organoid Technology
- Sakshi Garg, Lab Head, Discovery & Development Technologies, Merck Group
- Rhiannon David, Scientific Lead Microphysiological Systems, AstraZeneca
- Stephen J. fey, Founder and Chief Research Officer, CelVivo
- Alejandro Amador, Director, Cellular Assays and Technologies, Incyte
- Freddy Van Goethem, Scientific Director - Fellow, Predictive, Investigative, and Translational Toxicology, Johnson & Johnson; Janssen Pharmaceutical
- Julian Bahr, Postdoctoral Fellow, Oncology, AstraZeneca
- Pedro Pinto, Laboratory Manager, Urology, university of Greifswald – Medical Centre
WHO SHOULD ATTEND?
Biotech / Pharma Companies - Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor - Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO
Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer
